skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

開発中の医薬品をFDA承認確率で示すデータベース

Biomedtracker | Pharma intelligence

Biomedtracker(バイオメドトラッカー)では、アメリカの医薬品開発プロセスの動きを2003年以降独自に分析しています。弊社アナリストチームが下記に挙げる代表的なイベントと、それらによるインパクトを発生と同時に分析&評価し、アメリカ食品医薬品局(FDA)の承認確率(LOA: Likelihood of Approval)で提示します。そうすることで、医薬品の開発動向をいち早く正確に把握できるデータベースがBiomedtrackerです。

医薬品開発に大きな影響を与える代表的なイベントやカタリストの例:

  • 臨床試験の開始や結果報告
  • 学会やカンファレンスにおける発表
  • ライセンス、M&A、提携に関する活動
  • 企業発表(プレスリリース、収支報告、投資家向け情報)
  • 薬事行政の動向、など

Biomedtrackerをご利用いただくことのメリット:

公平性&即時性
第三者的立場からバイアスのないコメントを付与し、情報をほぼ即日更新します。

イベントの種類が豊富&検索可能
会社情報、特許、開発品の進捗、承認申請、臨床試験結果報告など275種類。過去のイベントは時系列で確認できます。

学会の情報収集など関連情報へのアクセス
アナリストが参加した学会のレポートを発行します(例: JP Morgan, ASCO, ASH, AAN, ATSなど)。お客様が参加することができなかった海外の学会に関する情報を収集できます。また、アメリカ食品医薬品局(FDA)諮問委員会での評価・投票結果やKOL(Key Opinion Leader)インタビュー、弊社が発行する様々なレポートにもアクセスできます。

Datamonitor Healthcareとの併用が効果的です
開発中医薬品をリアルタイムで追跡するBiomedtrackerは、医薬品の市場調査レポートライブラリーである姉妹サービスDatamonitor Healthcareとの併用が効果的です。ぜひ合わせてご検討ください。

 

【お知らせ】無料オンラインサービス説明会&トレーニングを開催します!
『開発品をFDA承認確率でみるBiomedtrackerについて』2018年10月10日(水)16時~17時、お申し込みはこちらから

このサービスの特徴

無料の最新記事&レポート

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Biopharma Partnering and Financing Trends, H1 2020 Whitepaper

    Biopharma Partnering and Financing Trends, H1 2020 Whitepaper

    Get an inside view into the trends powering COVID-era deal making in the life sciences with your free copy of “Biopharma Partnering and Financing Trends, H1 2020”. Informa Pharma Intelligence takes you inside the forces shaping the industry

    Topic Bio-Europe

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...

    Key Potential Drug Launches in 2021

    Valuable insight and expert analyst commentary 2021’s expected drug launches, their indications, commercial potential, regulatory catalysts and more.

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Pharma consulting: 医療用医薬品の...

    COVID-19 24 hour webinar recordings

    Catch up on any missed COVID-19 24 hour webinar sessions

    Topic Cardiovascular Coronavirus

  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biomedtracker: 開発中医...

    COVID-19 and the impact on the clinical trial space

    COVID-19 and the impact on the clinical trial space

    The effect of COVID-19 on clinical trials, the industry response, and the return to full operations

    Topic Coronavirus clinical-trials

  • Pharmaprojects: 医薬品開発パイプラインのデータベース, Biomedtracker: 開発中医薬品をFD...

    The Race to Find a COVID-19 Treatment - Infographic

    The Race to Find a COVID-19 Treatment - Infographic

    Access this infographic which focuses on Gilead’s drug Remdesivir which currently shows the greatest promise for the likelihood of approval as a possible treatment to effectively treat the virus. The infographic highlights the drug summary and profile, the number of patients in each trial phase, and the history of events that have moved this product through the development process.

    Topic Coronavirus FDA Drug Review

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    A Decade of Biopharma Mergers and Acquisitions and Outlook for 2020 Whitepaper

    A Decade of Biopharma Mergers and Acquisitions and Outlook for 2020 Whitepaper

    Using M&A activity as a barometer for the overall health of the biopharma industry, we explore biopharma’s biggest deals of the past decade and examine what they may presage for the year to come. Dive into key insights on trends, M&A drivers, companies to watch, and more. 

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    A Historic Decade of Deal Making

    A Historic Decade of Deal Making

    In preparation for the webinar, download your free infographic, a snapshot view of M&A’s biggest deals and major players and what their activities indicate for the year ahead.

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Trialtrove: 医療用医薬品の臨床試験情報デ...

    COVID-19 Infographic

    COVID-19 Infographic

    Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

    Topic Coronavirus

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Biomedtracker Potential Pivots in 2020

    Biomedtracker Potential Pivots in 2020

    In this infographic, we provide insight into key trials that are expecting developments in the approval process.

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...

    2020 Early Outlook Webinar

    Anticipate the biggest, most impactful expected catalysts of early 2020 with the guidance and insights from Pharma Intelligence. Building off Biomedtracker’s Early 2020 Outlook report, our live webinar will include market context for these upcoming milestones and additional insights from Datamonitor Healthcare’s Therapeutic Area Directors.

    Topic fda

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Meddevicetracker: 医療機器の市場調...

    38th Annual J.P. Morgan Healthcare Conference Review

    38th Annual J.P. Morgan Healthcare Conference Review

    The 38th Annual J.P. Morgan Healthcare Conference has concluded, and Biomedtracker and Meddevicetracker were there to bring you the important outcomes from the largest and most informative annual healthcare investment symposium in the industry.

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...

    2019 Post-ASH Conference Report Extract

    Access vital post-ASH meeting reporting from the expert analysts at Datamonitor Healthcare and Biomedtracker.

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...

    2019 Post-ESMO Conference Report Extract

    2019 Post-ESMO Conference Report Extract

    Tap into insights and highlights from ESMO’s annual meeting of oncology clinicians, researchers, patient advocates, journalists, and members of the pharmaceutical industry.

    Topic Cancer Drug development landscape Research

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Major Mergers & Acquisitions Highlights from Q1 2019

    Major Mergers & Acquisitions Highlights from Q1 2019

    Biomedtracker boils down all the important mergers and acquisitions activities in Q1.

    Topic Business strategies Company analysis

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Meddevicetracker: 医療機器の市場調...

    Q4 2019 Outlook Report Extract

    Q4 2019 Outlook Report Extract

    What major drug catalysts and events can you expect to see this quarter? Get a view of what's to come with an extract from the full report.

    Topic clinical-trials drug-development-landscape

製品説明を兼ねた無料デモ&お問い合わせ

専任スタッフによる詳しい説明を兼ねた無料デモンストレーションを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。